Manufacturer of Controlled Substances; Notice of Application; Wildlife Laboratories, Inc., 23958 [2013-09535]
Download as PDF
<![CDATA[
23958
Federal Register / Vol. 78, No. 78 / Tuesday, April 23, 2013 / Notices
CFR § 1301.34(b), (c), (d), (e), and (f) are
satisfied.
DEPARTMENT OF JUSTICE
Dated: April 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Manufacturer of Controlled
Substances; Notice of Application;
Research Triangle Institute
[FR Doc. 2013–09538 Filed 4–22–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
mstockstill on DSK4VPTVN1PROD with NOTICES
Importer of Controlled Substances:
Notice of Registration; Fisher Clinical
Services, Inc.
By Notice dated November 27, 2012,
and published in the Federal Register
on December 5, 2012, 77 FR 72409,
Fisher Clinical Services, Inc., 7554
Schantz Road, Allentown, Pennsylvania
18106, made application to the Drug
Enforcement Administration (DEA) to
be registered as an importer of
Levorphanol (9220), a basic class of
controlled substance in schedule II.
The company plans to import the
listed substances for analytical research
and clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and § 952(a),
and determined that the registration of
Fisher Clinical Services, Inc., to import
the basic class of controlled substance is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Fisher Clinical
Services, Inc., to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems; verification of the
company’s compliance with state and
local laws; and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and § 958(a), and in accordance
with 21 CFR 1301.34, the above named
company is granted registration as an
importer of the basic class of controlled
substance listed.
Dated: April 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–09537 Filed 4–22–13; 8:45 am]
BILLING CODE 4410–09–P
VerDate Mar<15>2010
17:51 Apr 22, 2013
Jkt 229001
Drug Enforcement Administration
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 26, 2013,
Research Triangle Institute, Poonam G.
Pande, Ph.D., RPH, RAC, Hermann
Building, East Institute Drive, P.O. Box
12194, Research Triangle Park, North
Carolina 27709, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
Drug
Schedule
Marihuana (7360) .........................
Cocaine (9041) .............................
I
II
The Institute will manufacture
marihuana, and cocaine derivatives for
use by their customers in analytical kits,
reagents, and reference standards as
directed by the National Institute on
Drug Abuse.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 24, 2013.
Dated: April 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
(DEA) to be registered as a bulk
manufacturer of Carfentanil (9743), a
basic class of controlled substance listed
in schedule II.
The company plans to manufacture
the above listed controlled substance for
sale to veterinary pharmacies, zoos, and
for other animal and wildlife
applications.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substance,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 24, 2013.
Dated: April 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2013–09535 Filed 4–22–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
S & B Pharma Inc.
By Notice dated May 31, 2012, and
published in the Federal Register on
June 8, 2012, 77 FR 34073, S & B
Pharma Inc., 405 South Motor Avenue,
Azusa, California 91702–3232, made
application to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
Drug
Schedule
[FR Doc. 2013–09533 Filed 4–22–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Wildlife Laboratories, Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 7, 2013,
Wildlife Laboratories Inc., 1230 W. Ash
Street, Suite D, Windsor, Colorado
80550, made application by renewal to
the Drug Enforcement Administration
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
Gamma
Hydroxybutyric
Acid
(2010).
Tetrahydrocannabinols (7370) .....
Methamphetamine (1105) ............
Pentobarbital (2270) .....................
Nabilone (7379) ............................
I
I
II
II
II
The company plans to manufacture
bulk controlled substances for use in
product development and for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
S & B Pharma Inc., to manufacture the
listed basic classes of controlled
substances is consistent with the public
E:\FR\FM\23APN1.SGM
23APN1
]]>Agencies
[Federal Register Volume 78, Number 78 (Tuesday, April 23, 2013)]
[Notices]
[Page 23958]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-09535]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application;
Wildlife Laboratories, Inc.
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on March 7, 2013, Wildlife
Laboratories Inc., 1230 W. Ash Street, Suite D, Windsor, Colorado
80550, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of
Carfentanil (9743), a basic class of controlled substance listed in
schedule II.
The company plans to manufacture the above listed controlled
substance for sale to veterinary pharmacies, zoos, and for other animal
and wildlife applications.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substance, may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than June 24, 2013.
Dated: April 16, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2013-09535 Filed 4-22-13; 8:45 am]
BILLING CODE 4410-09-P
